Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous ...

Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing ...

The pharmaceutical industry is undergoing a paradigm shift, driven by cutting-edge technologies and new digital capabilities.

"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

Current health news highlights include Pope Francis returning to ventilation for respiratory issues, Sun Pharma's ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

Emerging tools enable more accurate antigen production and presentation using mRNA instead of protein. In recent years, mRNA technology has come into its own, most prominently in the field of vaccine ...

Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United ...

Pfizer CEO Albert Bourla said on Monday that the drugmaker can shift manufacturing for the US market to its existing plants in the US, as the threat of tariffs puts a question mark over global supply ...

Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to ...

Discover top S&P 500 healthcare gainers & losers this week, key corporate updates, M&A news, and policy impacts shaping the healthcare sector's outlook.